Loading
Life sciences · Journal article
Biomolecules · October 14, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
The palliative and anti-cancer properties of CBD are attracting increasing attention. We have examined the dose-dependent effects of CBD on the viability and antitumor properties of human NK cells. CBD killed NK cells with an apparent IC50 of 77 μM at 24–48 h of incubation. Concentrations up to 10 μM caused neither cell death nor a significant decrease in metabolic activity, whereas concentrations above 30 μM provoked cell death. The antagonist of CB1 partly reverted CBD cytotoxicity, whereas the antagonist of CB2 was inefficient. Cyclosporin A (CsA), an inhibitor of the mitochondrial permeability transition pore, mPTP, strongly suppressed the CBD cytotoxicity. CBD produced the CsA-sensitive depolarization of mitochondrial membrane potential in leukemic Jurkat cells, with a lesser effect on NK cells. The cytotoxicity of NK cells against Jurkat cells was evaluated in a 1:1 co-culture. Different donors displayed greatly variable NK cells’ degranulation, which was unaffected by a pre-treatment with up to 25 μM of CBD. NK cells from half of the tested donors displayed maximal cytotoxicity against target cells upon pretreatment with up to 25 μM of CBD, whereas in others, NK cytotoxicity decreased by 60%. Therefore, the appropriateness of including CBD in anticancer treatment should be carefully assessed based on the concentrations expected for palliative or antitumor effects.